VX1 vs ElucidVivo A.3

Similar category, different focus. These tools serve overlapping but distinct needs. Comparability 60/100 Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.

VX1

by Volta Medical

ElucidVivo A.3

by Elucid

AI Verdict

Tool A (VX1) is an AI-powered solution for real-time guidance during cardiac ablation procedures, specifically focusing on electrogram analysis for atrial fibrillation and tachycardia. In contrast, Tool B (ElucidVivo A.3) is an AI-driven medical image analysis system that quantifies arterial plaque composition from CT angiography for atherosclerosis patient stratification. While both fall under cardiology AI, they address distinct clinical problems and utilize different data types, making them complementary rather than directly competitive.

Choose VX1 if…

Choose VX1 if your primary need is real-time, AI-guided assistance during cardiac ablation procedures for atrial fibrillation or atrial tachycardia. This tool is ideal for electrophysiologists seeking to enhance the precision and standardization of identifying dispersed electrograms during active surgical interventions.

View VX1 →

Choose ElucidVivo A.3 if…

Choose ElucidVivo A.3 if you require advanced, AI-powered quantitative analysis of arterial plaque composition from CT angiography to stratify atherosclerosis patients. This system is best suited for physicians needing detailed pre-procedural insights into plaque stability and characteristics to optimize treatment decisions and manage cardiovascular risk.

View ElucidVivo A.3 →

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Quick Comparison

Feature	VX1	ElucidVivo A.3
Pricing	Contact for pricing	Unknown
Deployment	Software integrated with existing electrophysiology (EP) lab mapping and recording systems.	Cloud and on-premise secure deployment.
FDA Status	Cleared AI-estimated	Cleared AI-estimated
HIPAA	Unknown	Yes AI-estimated

Head-to-Head

AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.

Usability

VX1

Volta Medical's VX1 features a 'Simple User Interface for Real-Time Regions of Interest Identification' and is described as 'intuitive, user-friendly' to avoid lengthening procedures. Its real-time guidance with visual and sound cues during a complex ablation procedure highlights a strong focus on seamless integration into a high-pressure clinical workflow.

Clinical Value

ElucidVivo A.3

ElucidVivo A.3 offers a unique, histologically-validated quantitative analysis of arterial plaque composition and stability from CT angiography, including the derivation of fractional flow reserve (FFRct). This provides profound and predictive insights for personalized atherosclerosis management, impacting patient stratification and treatment decisions for major cardiovascular events.

Pricing & Value

ElucidVivo A.3

While both tools require direct contact for pricing, ElucidVivo A.3's PlaqueIQ technology has secured broad reimbursement coverage from major payers like Medicare and United Healthcare. This indicates a recognized clinical and economic value proposition that supports its adoption and financial viability for healthcare institutions.

Enterprise Readiness

ElucidVivo A.3

Both tools are FDA-cleared and integrate with existing clinical systems. However, ElucidVivo A.3 explicitly states integration with PACS/EMR, which are central to enterprise imaging and patient data management. Its successful reimbursement coverage further solidifies its readiness for widespread adoption within healthcare enterprises.

Innovation

ElucidVivo A.3

ElucidVivo A.3 demonstrates greater innovation by providing the first FDA-cleared, histologically-validated software for non-invasive quantitative analysis of arterial plaque composition and stability from CT angiography. This capability, including FFRct derivation, offers new predictive insights for personalized atherosclerosis management, moving beyond traditional diagnostic assistance.

Support & Docs

VX1

Volta Medical's VX1 website explicitly provides access to its 'User Manual' and 'Brochure,' indicating readily available documentation for users. While Elucid Bioimaging provides contact information, readily accessible user manuals or extensive public documentation were not explicitly highlighted in the search results.

Feature-by-Feature

Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.

Feature	VX1	ElucidVivo A.3
Name	VX1	ElucidVivo A.3
Company	Volta Medical	Elucid Bioimaging
Primary Clinical Use	Assists cardiac electrophysiologists in real-time identification of dispersed electrograms during atrial fibrillation and atrial tachycardia ablation procedures.	Provides quantitative analysis of arterial plaque composition and stability from CT angiography for atherosclerosis patient stratification and treatment optimization.
Key AI Functionality	AI-guided real-time identification of dispersed electrograms (EGMs).	AI-powered quantitative analysis of arterial plaque (Lipid-Rich Necrotic Core, matrix, and calcifications).
Target Medical Specialties	Cardiology	Cardiology, Radiology, Vascular Surgery
Product Categories	Cardiology AI, Surgical AI	Cardiology AI, Radiology & Imaging AI

Videos

Demos, reviews, and walkthroughs featuring VX1 and ElucidVivo A.3.

Loading videos…

Videos need JavaScript to load. Search YouTube directly →

View all on YouTube

Frequently Asked Questions

What are the primary clinical applications of VX1 and ElucidVivo A.3?

Volta Medical's VX1 is designed to assist cardiac electrophysiologists in real-time identification of dispersed electrograms during atrial fibrillation and atrial tachycardia ablation procedures. In contrast, ElucidVivo A.3 by Elucid Bioimaging is an AI-powered medical image analysis system that provides quantitative analysis of arterial plaque composition and stability from CT angiography to aid in atherosclerosis patient stratification and optimize treatment decisions.

What type of patient data does each tool analyze?

VX1 analyzes 3D anatomical and electrical maps of human atria, specifically focusing on electrograms. ElucidVivo A.3 performs quantitative analysis of arterial plaque composition and stability from CT angiography images.

How does each tool assist physicians in real-time versus pre-procedural planning or diagnosis?

VX1 assists cardiologists in real-time during AFib and atrial tachycardia ablation procedures by identifying dispersed electrograms. ElucidVivo A.3 aids in stratifying patients with atherosclerosis and optimizing treatment decisions by providing detailed visualization and measurement of plaque characteristics from CT images, which is typically a pre-procedural or diagnostic assessment.

Which medical specialties are the primary beneficiaries of each tool?

VX1 is primarily for cardiology, specifically cardiac electrophysiologists. ElucidVivo A.3 benefits cardiologists, radiologists, and vascular surgeons.

What specific quantitative or qualitative insights does each tool provide to aid clinical decision-making?

VX1 provides AI-guided real-time identification of dispersed electrograms and offers cycle length estimation from electrograms, designed to reduce inter-operator variability and standardize outcomes. ElucidVivo A.3 objectively quantifies Lipid-Rich Necrotic Core (LRNC), matrix, and calcifications from CT images, visualizes lesion-level plaque composition, provides 3D visualization of highlighted vessels, and derives fractional flow reserve (FFRct) based on vessel wall vasodilative capacity.

How does each tool integrate into existing clinical workflows or lab environments?

VX1 is software integrated with existing electrophysiology (EP) lab mapping and recording systems. ElucidVivo A.3 is a software application that likely integrates with PACS/EMR systems, which is standard for medical imaging software.